ANTHEM Share Price | Anthem Biosciences Ltd Stock Analysis & Recommendation

Q: Is Anthem Bioscienc overvalued or undervalued?

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

Q: How has been the historical performance of Anthem Bioscienc?

Answer:The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.Breakdown:Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Q: When is the next results date for Anthem Biosciences Ltd?

The next results date for Anthem Biosciences Ltd is scheduled for February 5, 2026.

Q: Should I buy, sell or hold Anthem Biosciences Ltd?

Based on the current situation of Anthem Biosciences Ltd, it would be prudent to hold your position in the company. The high management efficiency is reflected in a strong return on equity (ROE) of 19.93%, and the company maintains a low debt-to-equity ratio, which is a positive indicator of financial stability. Additionally, the company has demonstrated impressive long-term growth, with net sales increasing at an annual rate of 29.80% and operating profit growing at 44.32%.However, recent quarterly results show some concerning trends, including a decline in profit after tax (PAT) by 14.1% compared to the previous four-quarter average and the lowest net sales recorded at Rs 423.15 crore. Furthermore, the valuation appears quite high with a price-to-book value of 14.6, which may suggest that the stock is expensive at this time.Given the combination of strong long-term growth potential and recent negative results, holding your investment could be a wise choice while monitoring the company's performance closely for any signs of recovery or further decline.

Q: Why is Anthem Biosciences Ltd falling/rising?

As of 05-May, Anthem Biosciences Ltd's stock price is currently at 760.90, reflecting a decrease of 3.2 points or 0.42%. The stock has underperformed its sector by 0.52% today, which may contribute to the decline in price. Additionally, there has been a significant drop in investor participation, with delivery volume on May 4 falling by 60.22% compared to the 5-day average. This decline in trading activity can indicate reduced interest from investors, which often leads to downward pressure on stock prices.Despite these short-term challenges, the company has shown strong performance over longer periods, with a year-to-date increase of 16.87%, significantly outperforming the Sensex, which has decreased by 9.63% during the same timeframe. Furthermore, Anthem Biosciences Ltd has demonstrated high management efficiency, being net-debt free, and has experienced healthy long-term growth with net sales growing at an annual rate of 29.80% and operating profit at 44.32%. The increasing participation of institutional investors, who have raised their stake by 3.87% in the last quarter, also indicates a positive outlook for the company.In summary, the current decline in stock price can be attributed to short-term underperformance and reduced trading volume, despite the company's strong fundamentals and positive long-term growth indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.22 lacs (33.11%) Volume

Shareholding (Mar 2026)

FII

1.28%

Held by 37 FIIs

DII

0.50%

Held by 26 DIIs

Promoter

74.68%

Is Anthem Bioscienc overvalued or undervalued?

01-Sep-2025

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

View full answer

How has been the historical performance of Anthem Bioscienc?

09-Nov-2025

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

View full answer

When is the next results date for Anthem Biosciences Ltd?

28-Jan-2026

The next results date for Anthem Biosciences Ltd is February 5, 2026.

View full answer

Should I buy, sell or hold Anthem Biosciences Ltd?

11-Apr-2026

Why is Anthem Biosciences Ltd falling/rising?

06-May-2026

As of 05-May, Anthem Biosciences Ltd's stock price is at 760.90, down 0.42%, due to short-term underperformance and reduced trading volume. However, the company shows strong long-term growth and fundamentals, with a year-to-date increase of 16.87% and rising institutional investor interest.

View full answer

Which are the latest news on Anthem Bioscienc?

06-May-2026

Anthem Biosciences Ltd is Rated Hold by MarketsMOJO
Anthem Biosciences Ltd is Rated Hold

Compare Anthem Bioscienc with Similar Stocks

Abbott India Glaxosmi. Pharma Biocon

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 19.93%

The company is Net-Debt Free

Healthy long term growth as Net Sales has grown by an annual rate of 29.80% and Operating profit at 44.32%

Negative results in Dec 25

With ROE of 17.7, it has a Very Expensive valuation with a 15.1 Price to Book Value

Increasing Participation by Institutional Investors

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 43,033 Cr (Mid Cap)

P/E

86.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.34

Return on Equity

17.74%

Price to Book

15.02

Revenue and Profits:

Net Sales:

423 Cr

(Quarterly Results - Dec 2025)

Net Profit:

93 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

17.62%

6 Months

10.33%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Anthem Bioscienc for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Anthem Biosciences Ltd is Rated Hold by MarketsMOJO

Anthem Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Anthem Biosciences Ltd is Rated Hold

Anthem Biosciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 April 2026. While the rating change occurred on that date, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 24 April 2026.

Read full news article

Anthem Biosciences Ltd Upgraded to Hold on Technical and Financial Reassessment

Anthem Biosciences Ltd has seen its investment rating upgraded from Sell to Hold as of 10 April 2026, reflecting a notable improvement in technical indicators alongside steady fundamental performance despite recent quarterly setbacks. The mid-cap pharmaceutical and biotechnology company’s Mojo Score has risen to 50.0, signalling a more balanced outlook for investors amid mixed financial trends and valuation concerns.

Read full news article

Announcements

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

30-Apr-2026 | Source : BSE

Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No.	Particulars	Details
1	Name of Company	Anthem Biosciences Ltd
2	CIN NO.	U24233KA2006PLC039703
3	Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)	2.96
4	Highest Credit Rating during the previous FY	NA
4a	Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)	Not Applicable
5	Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework	BSE

We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No

Name of the Company Secretary: Divya Prasad
Designation: Company Secretary and Compliance Officer
EmailId: divya.p@anthembio.com

Name of the Chief Financial Officer: Mohammed Gawir Baig
Designation: Chief Financial Officer
EmailId: gawir.b@anthembio.com

Date: 30/04/2026

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Announcement Under Regulation 30 Of LODR-Update In The Outcome Of The Board Meeting Held On April 22 2026

22-Apr-2026 | Source : BSE

Submission of the Outcome of the Board Meeting held on April 22 2026

Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

22-Apr-2026 | Source : BSE

Submission of approval by the Board of Directors the appointment of M/s. S.R. Batliboi & Associates LLP as the Statutory Auditors of the Company at its Meeting held on April 22 2026 subject to the approval of the Shareholders.

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.80%

EBIT Growth (5y)

44.32%

EBIT to Interest (avg)

56.77

Debt to EBITDA (avg)

0.16

Net Debt to Equity (avg)

-0.25

Sales to Capital Employed (avg)

0.62

Tax Ratio

28.85%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.83%

ROCE (avg)

32.59%

ROE (avg)

19.93%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

15.15

EV to EBIT

69.13

EV to EBITDA

61.31

EV to Capital Employed

22.53

EV to Sales

22.95

PEG Ratio

Dividend Yield

ROCE (Latest)

32.59%

ROE (Latest)

17.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 27 Schemes (10.12%)

FIIs

Held by 37 FIIs (1.28%)

Promoter with highest holding

Ajay Bhardwaj (42.53%)

Highest Public shareholder

Portsmouth Technologies Llc . (2.74%)

Individual Investors Holdings

9.38%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "416.58",
          "val2": "552.23",
          "chgp": "-24.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "163.05",
          "val2": "225.66",
          "chgp": "-27.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.13",
          "val2": "2.23",
          "chgp": "-49.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "112.12",
          "val2": "198.43",
          "chgp": "-43.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.14%",
          "val2": "40.86%",
          "chgp": "-1.72%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,090.24",
          "val2": "863.40",
          "chgp": "26.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "421.08",
          "val2": "324.04",
          "chgp": "29.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.84",
          "val2": "5.20",
          "chgp": "-26.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "346.77",
          "val2": "255.63",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.62%",
          "val2": "37.53%",
          "chgp": "1.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,506.82",
          "val2": "1,361.66",
          "chgp": "10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "584.13",
          "val2": "490.89",
          "chgp": "18.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.97",
          "val2": "6.99",
          "chgp": "-28.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-24.98",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "458.89",
          "val2": "383.62",
          "chgp": "19.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "38.77%",
          "val2": "36.05%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,840.65",
          "val2": "1,417.54",
          "chgp": "29.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "689.01",
          "val2": "504.89",
          "chgp": "36.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.09",
          "val2": "9.14",
          "chgp": "-0.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "506.19",
          "val2": "374.78",
          "chgp": "35.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.43%",
          "val2": "35.62%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

416.58

552.23

-24.56%

Operating Profit (PBDIT) excl Other Income

163.05

225.66

-27.75%

Interest

1.13

2.23

-49.33%

Exceptional Items

-24.98

0.00

Standalone Net Profit

112.12

198.43

-43.50%

Operating Profit Margin (Excl OI)

39.14%

40.86%

-1.72%

Values in Rs Cr.

Compare with Peers

Net Sales
QoQ Growth in quarter ended Dec 2025 is -24.56% vs 2.64% in Sep 2025

Standalone Net Profit
QoQ Growth in quarter ended Dec 2025 is -43.50% vs 33.77% in Sep 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

1,090.24

863.40

26.27%

Operating Profit (PBDIT) excl Other Income

421.08

324.04

29.95%

Interest

3.84

5.20

-26.15%

Exceptional Items

0.00

Standalone Net Profit

346.77

255.63

35.65%

Operating Profit Margin (Excl OI)

38.62%

37.53%

1.09%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,506.82

1,361.66

10.66%

Operating Profit (PBDIT) excl Other Income

584.13

490.89

18.99%

Interest

4.97

6.99

-28.90%

Exceptional Items

-24.98

0.00

Standalone Net Profit

458.89

383.62

19.62%

Operating Profit Margin (Excl OI)

38.77%

36.05%

2.72%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

1,840.65

1,417.54

29.85%

Operating Profit (PBDIT) excl Other Income

689.01

504.89

36.47%

Interest

9.09

9.14

-0.55%

Exceptional Items

0.00

Standalone Net Profit

506.19

374.78

35.06%

Operating Profit Margin (Excl OI)

37.43%

35.62%

1.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Anthem Biosciences Ltd

Anthem Biosciences Ltd

Mid Cap

Pharmaceuticals & Biotechnology

Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.